UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development

Drug metabolism and disposition, 2012-08, Vol.40 (8), p.1495-1507

2012

Volltextzugriff (PDF)

Abnormal brain structure and behavior in MyD88-deficient mice

Brain, behavior, and immunity, 2021-01, Vol.91, p.181-193

2021

Volltextzugriff (PDF)

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

Antimicrobial agents and chemotherapy, 2014-06, Vol.58 (6), p.3233-3244

2014

Volltextzugriff (PDF)

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

CPT: pharmacometrics and systems pharmacology, 2018-03, Vol.7 (3), p.135-146

2018

Volltextzugriff (PDF)

Staging the Blues: From Tent Shows to Tourism by Paige A. McGinley (review)

African American review, 2015-12, Vol.48 (4), p.478-480

Schroeder, Patricia R

2015

Volltextzugriff (PDF)

Neo-Hoodoo Dramaturgy: Robert Johnson on Stage

African American review, 2015-03, Vol.48 (1/2), p.83-96

Schroeder, Patricia R.

2015

Volltextzugriff (PDF)

Oedipus Rex by Sophocles, Italian translation by Guido Paduano, directed by Daniele Salvo (review)

Theatre journal (Washington, D.C.), 2014-03, Vol.66 (1), p.128-129

Schroeder, Patricia R

2014

Volltextzugriff (PDF)

From the Archive: “Why the AAP is Not Waging War on Librarians” (2001)

Charleston advisor, 2024-07, Vol.25 (5), p.47-47

Schroeder, Patricia S.

2024

Volltextzugriff (PDF)

Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator

European journal of pharmacology, 2011-06, Vol.659 (2), p.146-154

2011

Volltextzugriff (PDF)

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Drug metabolism and disposition, 2008-09, Vol.36 (9), p.1780-1785

2008

Volltextzugriff (PDF)

Abstract 3368: Pre-clinical PK/PD/efficacy characterization of AZD1480, a JAK1/2 kinase inhibitor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3368-3368

Schroeder, Patricia

2013

Volltextzugriff (PDF)

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

Drug metabolism and disposition, 2005-09, Vol.33 (9), p.1367-1372

2005

Volltextzugriff (PDF)

Passing for Black: Coon Songs and the Performance of Race

Journal of American culture (Malden, Mass.), 2010-06, Vol.33 (2), p.139-153

Schroeder, Patricia R.

2010

Volltextzugriff (PDF)

Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor

Journal of Toxicologic Pathology, 2014, Vol.27(1), pp.31-42

2014

Volltextzugriff (PDF)

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Molecular pharmacology, 2003-09, Vol.64 (3), p.670-678

2003

Volltextzugriff (PDF)

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)

Drug metabolism and disposition, 2002-12, Vol.30 (12), p.1431-1435

2002

Volltextzugriff (PDF)

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

Cancer chemotherapy and pharmacology, 2002-12, Vol.50 (6), p.509-513

2002

Volltextzugriff (PDF)

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

The Journal of pharmacology and experimental therapeutics, 2022-03, Vol.380 (3), p.210-219

2022

Volltextzugriff (PDF)

Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks

Blood, 2021-11, Vol.138 (Supplement 1), p.9-9

2021

Volltextzugriff (PDF)

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study

Blood, 2021-11, Vol.138 (Supplement 1), p.8-8

2021

Volltextzugriff (PDF)

Healthcare quality improvement: Then and now

Nursing management, 2019-09, Vol.50 (9), p.20-25

2019

Volltextzugriff (PDF)

P233 - Quantification of pravastatin uptake into rat, dog, monkey and human plated cryopreserved hepatocytes in the presence and absence of bovine serum albumin

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S93-S93

2020

Volltextzugriff (PDF)

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.19-20

2020

Volltextzugriff (PDF)

1 – 25 von 546

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(431)
Mit Volltextzugriff
(465)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(131)
Humans
(69)
Animals
(44)
Biological And Medical Sciences
(31)
Pharmacology & Pharmacy
(28)
Nonfiction
(22)
Medical Sciences
(21)
Male
(20)
Physical Sciences
(20)
Childrens Literature
(19)
Rats
(17)
Science & Technology - Other Topics
(17)
Social Sciences
(17)
Mice
(14)
Neurosciences
(14)
Nursing
(14)
Neurosciences & Neurology
(13)
Parents & Parenting
(13)
Multidisciplinary Sciences
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development

Abnormal brain structure and behavior in MyD88-deficient mice

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Staging the Blues: From Tent Shows to Tourism by Paige A. McGinley (review)

Neo-Hoodoo Dramaturgy: Robert Johnson on Stage

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Oedipus Rex by Sophocles, Italian translation by Guido Paduano, directed by Daniele Salvo (review)

From the Archive: “Why the AAP is Not Waging War on Librarians” (2001)

Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Abstract 3368: Pre-clinical PK/PD/efficacy characterization of AZD1480, a JAK1/2 kinase inhibitor

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

Passing for Black: Coon Songs and the Performance of Race

Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study

Healthcare quality improvement: Then and now

P233 - Quantification of pravastatin uptake into rat, dog, monkey and human plated cryopreserved hepatocytes in the presence and absence of bovine serum albumin

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

Aktive Filter

Suchergebnisse filtern